Navigation Links
Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
Date:11/9/2007

WASHINGTON, Nov. 9 /PRNewswire-USNewswire/ -- The Community Oncology Alliance (COA), representing community cancer centers nationwide, formally requested that the Centers for Medicare & Medicaid Services (CMS) reconsider its decision to restrict the access of senior cancer patients to vital anemia-fighting drugs. Effective July 30, 2007, CMS implemented a National Coverage Determination (NCD) limiting oncologists' use of anemia-fighting drugs, referred to as Erythopoiesis Stimulating Agents (ESAs) in Medicare cancer patients undergoing chemotherapy treatment. Anemia is a common side effect of chemotherapy, and ESAs are used to minimize the need for red blood cell transfusions.

According to Dr. Patrick Cobb, a practicing oncologist from Billings, Montana, and Chairman of the COA Clinical Practices Committee, "What prompted this recent request to CMS to reconsider its decision to restrict ESA use was the release on November 8, 2007 of revised FDA-approved labeling for ESAs." Dr. Cobb added, "Unfortunately, what FDA considers safe and effective ESA use, CMS does not. As a result, our Medicare patients are not receiving the same standard of care as our younger patients."

The ESA labeling revisions include additional warnings related to risks associated with the use of ESAs "when dosed to target a hemoglobin of >= 12 g/dL" and instructs physicians to "use the lowest dose needed to avoid red blood cell transfusions" in order to minimize risk. However, the FDA specifically notes in both the revised label and its accompanying press release dated November 8, 2007 that, "no clinical data is available" to establish the risk of using ESAs when hemoglobin levels are less than 12 g/dL. The CMS NCD, on the other hand, arbitrarily prohibits ESA use when hemoglobin levels are 10 g/dL or higher.

"We use ESAs to reduce the need to give our patients transfusions, so we don't expose them to undue risks," said Dr. Cobb. "ESAs are important drugs, as are all the therapies we use to treat our patients--patient safety is always our primary concern. However, what CMS has done is to actually limit our ability to use ESAs in a way that minimizes transfusions."

In its reconsideration letter to CMS, COA notes, "It is readily apparent the CMS NCD essentially overrules the FDA scientific expertise by deeming ESAs unsafe and ineffective when used in the range of >=10 g/dL and <12 g/dL. Equally distressing is the fact that CMS is using a reimbursement policy to substitute its own clinical judgment, rather than allowing physicians to exercise their own clinical judgment for each individual patient's circumstances, as recommended in the newly revised FDA-approved label." COA further notes, "there is evidence to suggest that initiating ESA treatment at a hemoglobin level >10 g/dL significantly reduces the risk of transfusion."

COA is asking CMS for immediate reconsideration of the portions of the NCD dealing with cancer patients undergoing chemotherapy.

For additional information contact Ted Okon, COA Executive Director, taokon@sosacorn.com, 203-715-0300.

The Community Oncology Alliance (COA) is a non-profit organization. The mission of COA is to foster and protect the community oncology delivery system in the United States through public policy, advocacy, and education. Eighty-four percent of Americans battling cancer receive high quality, affordable, and accessible cancer care in community oncology clinics close to home. The accessibility of high quality cancer care, coupled with earlier diagnosis and new therapies, has resulted in a decreased cancer mortality rate.


'/>"/>
SOURCE Community Oncology Alliance
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
3. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
4. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... nutrition division of Diplomat Specialty Infusion Group, is celebrating a decade of ... To celebrate its anniversary, ThriveRx recently launched a redesigned website at ... organization to create the best user experience for consumers and health care ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 ...
(Date:7/5/2017)... July 5, 2017 Pace Analytical, a company of over 2,000 employees ... they have acquired ESC Lab Sciences, further solidifying their position as the top ... . ... President and CEO of Pace Analytical ... Sciences out of Mt Juliet, TN , enhances Pace Analytical,s ...
(Date:6/30/2017)... , June 30, 2017 In vitro ... the start of May, at least ten diagnostic companies ... private investments, public offerings and a loan facility.  The ... to almost $80 million.  Kalorama Information provides a monthly ... its Diagnostics Knowledge Center. ...
Breaking Medicine Technology:
(Date:7/24/2017)... TX (PRWEB) , ... July 24, 2017 , ... ... student scholarship will be awarded for the fall semester to a deserving student. ... Emergency Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill ... a unique opportunity that helps high school girls succeed in STEM programs as ... Horizon Goodwill will host over 20 high school girls at their corporate ...
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum in ... take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland Rockside ... a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is sponsored ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... of media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin ... is one of the leading causes of long term skin conditions, including cancer. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global leader ... issuance of United States Patent Number 9,695,398 (the '398 patent) and South Korean ... '398 and '324 patents cover methods and systems for optimizing fat grafts for ...
Breaking Medicine News(10 mins):